Primary vs Secondary Endpoints: What a Trial Really Has to Prove
The primary endpoint is the main measure a clinical trial is designed to test, fixed before the trial starts, such as survival time or a drop in a symptom score. Secondary endpoints are other measures the trial also tracks. If a trial misses its primary endpoint, wins on secondary endpoints rarely save it, and a small biotech's stock usually falls hard.
Primary vs secondary endpoints
Before a trial starts, the company and the FDA agree on what success looks like. That is the primary endpoint, and the trial's size is calculated so it can show a real difference on that measure.
Secondary endpoints are the supporting cast: other symptoms, quality of life, longer-term outcomes. They are tested in a set order, and in most trials a secondary result only counts statistically if the primary endpoint was met first.
What a missed primary endpoint does to a stock
aTyr Pharma's Phase 3 missed its primary endpoint in September 2025. The stock went from $6.03 to about $1 in a day, down 83%.
Agios is a subtler case. In November 2025 its sickle cell Phase 3 met one of its two primary endpoints but missed the other, and the stock fell about half in one day. When a trial has two primary endpoints, the market usually wants both.
Companies sometimes lead a press release with a secondary win after a primary miss. Read the first paragraph carefully: if it doesn't say the primary endpoint was met, it probably wasn't.
How to read endpoints before the result
- Find the primary endpoint on ClinicalTrials.gov. It is listed for every registered trial.
- Ask if it matters to doctors. Survival and symptom relief count for more than a lab marker.
- Check for more than one primary endpoint. Two means two chances to miss.
- Watch for changes. A primary endpoint changed late in a trial can be a warning sign.
See it live: Upcoming readouts with phase, design and completion date, so you know which results are coming and when.
Open the Catalyst Screener →Frequently asked questions
It is the main result a clinical trial is designed to measure, agreed before the trial starts. Whether the trial succeeds is judged on this endpoint.
An additional measure the trial tracks, such as quality of life or a related symptom. It supports the primary result but usually can't replace it.
The drug usually can't be approved on that trial alone. For a small biotech the stock often falls sharply; aTyr Pharma fell 83% in a day after its Phase 3 missed in September 2025.
Rarely. Secondary results are generally treated as supportive unless the primary endpoint was met first.
On ClinicalTrials.gov, under the trial's NCT number, in the outcome measures section.
Educational content only. Not financial advice. Past results don't predict future ones.